Sun Pharmaceutical Industries Limited Share Price & Stock Analysis

Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA, BSE: 524715) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹4,56,425 Cr, it ranks #15 by market cap among the 6,197 Indian listed companies on FinBizNet, and #1 of 86 in Medicinal Chemicals and Botanical Products. At ₹1,880.00 (as of 16 Nov 2026), the share price is 8.2% below its 52-week high of ₹2,046.90 and 18.7% above its 52-week low of ₹1,583.70. The share price is up 11.2% over one year and down 2.7% over three months.

Key Metrics

Current Price₹1,880.00
Market Cap₹4,56,425 Cr
NSE SymbolSUNPHARMA
BSE Code524715
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Medicinal Chemicals and Botanical Products
P/E Ratio39.5
Return on Equity14.72%
Return on Assets8.47%
52-Week Range₹1,583.70 – ₹2,046.90
1-Year Price Change+11.2%
3-Month Price Change-2.7%
Beta (1Y)-0.19
Dividend Yield0.53%
HeadquartersMumbai, Maharashtra
Websitesunpharma.com

Latest Quarterly Results — Q2 FY27

Revenue₹16,199 Cr
Net Profit₹1,995 Cr
Net Margin12.3%
EPS (Basic)₹8.30
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Sun Pharmaceutical Industries Limited Quarterly Revenue and Profit Trend

Sun Pharmaceutical Industries Limited reported revenue of ₹16,199 Cr in Q2 FY27, up 11.9% from ₹14,478 Cr in Q2 FY26 and up 5.9% from ₹15,300 Cr in Q1 FY27. It posted a net profit of ₹1,995 Cr for the quarter, against a net profit of ₹3,125 Cr in Q2 FY26 (down 36.2%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹12,959 Cr (Q4 FY25) to ₹16,199 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹16,199 Cr₹1,995 Cr12.3%
Q1 FY27₹15,300 Cr₹2,901 Cr19.0%
Q4 FY26₹14,612 Cr₹2,710 Cr18.5%
Q3 FY26₹15,521 Cr₹3,381 Cr21.8%
Q2 FY26₹14,478 Cr₹3,125 Cr21.6%
Q1 FY26₹13,851 Cr₹2,293 Cr16.6%
Q4 FY25₹12,959 Cr₹2,154 Cr16.6%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 52.68% of Sun Pharmaceutical Industries Limited's shares as of Sept 2026, against 54.48% in Sept 2025 (−1.80 percentage points). Delivery averaged 58.3% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, urology, dermatology, respiratory, dental, and nutritionals. It also provides generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications; antiretrovirals medications; and over-the-counter products, such as vitamins, analgesics, digestives, and lifestyle. In addition, the company offers APIs for anti-cancers, peptides, steroids, sex hormones, immunosuppressant drugs, and controlled substances. It exports its p

Products and Services

1. Pharmaceuticals-This segment manufactures, develops, and markets branded and generic formulations, and active pharmaceutical ingredients.

Business Segments

1. Pharmaceuticals-100%

Sun Pharmaceutical Industries Limited vs Peers — Medicinal Chemicals and Botanical Products

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Sun Pharmaceutical Industries Limited₹4,56,425 Cr39.514.72%₹16,199 Cr+11.2%
Laurus Labs Ltd₹1,31,242 Cr145.617.74%₹2,206 Cr+146.8%
Zydus Lifesciences Ltd₹1,19,651 Cr24.118.32%₹7,910 Cr+26.0%
Dr.Reddys Lab₹1,15,464 Cr26.911.52%₹8,698 Cr+14.5%
Cipla Limited₹1,14,712 Cr29.311.74%₹7,404 Cr-7.6%
Mankind Pharma₹1,09,870 Cr5712.45%₹4,338 Cr+16.7%
Aurobindo Pharma Ltd.₹1,05,150 Cr309.93%₹10,263 Cr+59.8%
Lupin Ltd₹92,087 Cr17.326.91%₹7,827 Cr+0.4%
Glenmark Pharmaceuticals Limited₹75,556 Cr55.114.07%₹4,157 Cr+45.7%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Sun Pharmaceutical Industries Limited?

Sun Pharmaceutical Industries Limited is trading at ₹1,880.00, with a market capitalisation of ₹4,56,425 Cr.

Which sector does Sun Pharmaceutical Industries Limited belong to?

Sun Pharmaceutical Industries Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).

What are the key financial ratios of Sun Pharmaceutical Industries Limited?

Sun Pharmaceutical Industries Limited has a P/E of 39.5 and a return on equity of 14.72%.

What is the stock symbol of Sun Pharmaceutical Industries Limited?

Sun Pharmaceutical Industries Limited is listed on the NSE under the symbol SUNPHARMA and on the BSE under the scrip code 524715.

How has Sun Pharmaceutical Industries Limited's share price moved over the past year?

Sun Pharmaceutical Industries Limited's share price is up 11.2% over one year and down 2.7% over three months. Its 52-week range is ₹1,583.70 to ₹2,046.90.

What were Sun Pharmaceutical Industries Limited's latest quarterly results?

In Q2 FY27, Sun Pharmaceutical Industries Limited reported revenue of ₹16,199 Cr and net profit of ₹1,995 Cr, with basic EPS of ₹8.3 (consolidated, parsed from the company's exchange filing).

How have Sun Pharmaceutical Industries Limited's revenue and profit changed over the past year?

Sun Pharmaceutical Industries Limited reported revenue of ₹16,199 Cr in Q2 FY27, up 11.9% from ₹14,478 Cr in Q2 FY26 and up 5.9% from ₹15,300 Cr in Q1 FY27.

What is the promoter holding in Sun Pharmaceutical Industries Limited?

Promoters held 52.68% of Sun Pharmaceutical Industries Limited's shares as of Sept 2026, against 54.48% in Sept 2025 (−1.80 percentage points).

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.